AURORA, ON- Helix BioPharma Corp. , a biopharmaceutical business establishing treatment prospects the prohibition and therapy of cancers, right announced that it’s going to file a type 15F by using the usa investments and trade charge (the “SEC”) with all the goal of terminating enrollment of the common carries under point 12(g) with the U . S . investments Exchange Act of 1934, as revised (the “trade function”) and terminating its reporting duties for every of the subscribed investments under segment 15(d) with the swap function.
As before revealed, Helix has voluntarily delisted its typical part from the NYSE MKT. On June 9, 2012, Helix recorded a type 25 because of the SEC to trigger the voluntary delisting, which started to source site be effective on July 19, 2012. On July 18, 2012, Helix recorded a Post-Effective Amendment to the Registration report on type F-10 with all the SEC, eliminating from enrollment all unsold securities.